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eMethods and eResults 
Data Quality Assurance and Exclusion 
For each ROI extracted with FreeSurfer, histograms were created from each site’s data to investigate the normality of the data 
distribution, and statistical outliers were identified. If the mean of an individual’s subcortical volume was more than 3 standard 
deviations from the mean for the site, it was flagged for a more extensive quality control and possible removal from the analysis. 
Participants with an ROI volume greater than five standard deviations from the mean across sites were removed. The initial 
number of participants from each study with MRI, and the number of participants excluded are found in eTable 3. Exclusion 
criteria at this stage included 1) missing clinical or demographic data, 2) any MRI artifacts, gross anatomical abnormalities, or 
regional volumes failing quality assurance, or 3) an ROI volume greater than five standard deviations from the mean across 
sites. An additional four transgender individuals across two sites were excluded.  
Reporting of Effect Sizes 
Effect sizes for dichotomous variables were estimated by converting t-values from random effects multiple linear regressions 




where 𝑛1 and 𝑛2 are the sample size for each group. For continuous variables, effect sizes were estimated by converting t-




For both equations, 𝑑𝑓 is the degrees of freedom as outputted by the ‘nlme’ package in R (version 3.2.3). 
Age Feasibility Study Mega-Analysis  
To ensure sufficient power to detect associations between brain measures and variables of interest from data pooled across 
studies, a preliminary analysis tested for associations between age and eight brain volumes. Random effects multivariable linear 
regressions were performed. Three fixed-effects covariates were included in the model: sex, the interaction between age and 
sex, and estimated total intracranial volume to adjust for variability in head size. To account for scanner effects, the data 
collection site was used as the random-effects grouping variable; there were 19 sites in all. Statistical analyses were conducted 
with the ‘nlme’ package in R (version 3.2.3). Effect sizes were estimated using the r-value (partial correlation coefficients) 
after accounting for all covariates. Significance was determined using the Bonferroni correction threshold (p ≤ 0.0063). 
Across the entire sample (N=1,203), older age was associated with smaller volumes of all subcortical structures and larger 
ventricular volumes (r-value range: 0.13-0.30), consistent with studies in seronegative adults1. Sex was a significant predictor 
in models for associations between age and the thalamus, putamen, globus pallidus, hippocampus, and amygdala (p ≤ 0.0063). 
Age effects in the subset of participants taking cART, males, and females mirrored that of the full group. Participants not taking 
cART showed significant associations between age and caudate, putamen, globus pallidus, nucleus accumbens, and ventricular 
volumes. No significant age by sex interaction was detected. 
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HIV Subcortical Volume Comparisons with Healthy Lifespan Centiles 
In a recent study from the ENIGMA lifespan working group, subcortical volume trajectories across the lifespan were 
derived from 18,605 healthy participants pooled from 88 international samples2. As there was a lack of site and scanner 
matched HIV-negative controls in our ENIGMA-HIV sample, we used the centile curves to extrapolate how subcortical 
volumes in HIV+ individuals compared to age-matched healthy individuals. Given the wide variability in population 
demographics and scanners from which the volumes were extracted and reported curves estimated, they may incorporate 
sufficient variability to serve as a surrogate for matched controls. 
For each subcortical volume, we used the discrete centile values reported for every 10 years of age in Dima et al. 
supplementary Table S6 to estimate whether the distribution of volumes in our HIV+ sample are similar to that expected 
for an age-matched healthy population. 
We did this under the assumptions that: 
1. for each volume, at each age provided, the distribution of volumes across the population was Gaussian, and
2. for all ages between those provided, (e.g, any age between 40 and 50), the distribution could be estimated by
linearly interpolating the mean and variance of the data from the two closest ages. Note: In Dima et al. Table
S6, the ages for which centile volumes are reported span 20 to 90 years of age discretized at 10-year intervals.
We used the 50th centile (C50; 50th percentile) column as the mean of the distribution and estimated the standard deviation 
by assuming that the 75th centile (C75) is 0.674 standard deviations above the mean, as would be the case for a Gaussian 
distribution. Therefore, as z = (x-µ)/σ, we calculated the standard deviation for each structure, at each age provided, using 
the formula: 
σage = (C75 - C50)*0.674 
As the centiles were calculated non-parametrically, the distribution was not exactly Gaussian; the standard deviation 
calculated from the 25th centile was (in nearly all cases) smaller than that calculated with the 75th centile. Assuming a 
wider distribution is a more conservative approach as it is harder to reject the null with greater variability or more noise; 
we therefore used the larger of the two estimates. 
Next, for each age represented in our HIV+ sample, we estimated the distribution of each subcortical volume by linearly 
interpolating the volumes at the provided surrounding ages (e.g., 40 and 50 for someone 43 years of age). As each 
individual’s volume is from a different distribution, we standardized the subject-level volumes by converting them to z-
scores and percentile estimates: (1) We first determined the z-score associated with the observed volume of that subject 
with respect to that expected distribution; (2) Then, for each individual observation, we randomly sampled 10,000 instances 
from the expected distribution and determined how many times the observed volume was less than or equal to the randomly 
drawn volumes. This resulted in an approximate percentile for the individual. 
The probability density function (pdf) for the set of 1,203 paricipants’ z-scores for each volume was then compared to the 
pdf of 1,203 randomly sampled draws from the standard normal distribution. The Kullback–Leibler divergence was then 
calculated using the KLD function from the "LaplacesDemon" library available in R, and the intrinsic discrepancy was 
used as a measure of deviation between the two distributions. These KLD values are provided in eTable 6. To determine 
whether this deviation was greater than would be expected by chance, and derive a non-parametric p-value estimate, we 
drew 1,203 random values from the normal distribution and used the KLD intrinsic discrepancy measure to compare their 
pdf to that obtained from the original random sample to which we compared the pdf of the HIV+ distribution; we then 
repeated this 10,000 times to determine how many times the observed was less than the random sample. The number of 
© 2021 T. M. Nir et al. JAMA Network Open. 
times our observation was less extreme (or one, whichever was greater) was then divided by total number of permutations 
to derive a p-value for the divergence. 
A second method for determining whether the observed volumes were likely to come from the distributions derived from 
healthy controls made use of the percentiles derived as described above. If the set of HIV+ observations was derived from 
the healthy distribution, the percentiles are likely to be uniformly distributed. Therefore, we binned a uniform distribution 
[0,1] into 100 bins and performed a chi-squared goodness of fit test to determine whether the observed percentiles were 
approximately uniformly distributed. The chi-squared test was performed using the “chisq.test” function in R, with 10,000 
simulated values. These p-values are also provided in eTable 6. 
We note, all volumes for our HIV+ population appear to be from distributions that are not those described using healthy 
control data from multiple international imaging centers. Therefore, we anticipate significant case/control differences are 
likely across all structures, although the lack of HIV-negative controls from all sites prevented us from testing this directly. 
For approximate visualization of distributions, we tabulated the number of HIV+ individuals in a given age range whose 
subcortical volumes fell between each pair of healthy centile values (e.g., for the hippocampus, how many HIV+ 
individuals ≤ 25 years of age and > 35 years fell between the C10 (10th percentile) and C25 (25th percentile) hippocampal 
volume values for age 30). The resulting histograms are shown in eFigures 3-6. 
Validation Analyses 
Two sets of validation analyses were performed: 1) dichotomizing CD4+ cell count based on the AIDS-defining threshold 
of 200/μL; and 2) defining a common dVL threshold across sites (400 copies/mL, the highest detection limit for any site). 
As in the primary analyses, multivariable random effects linear regressions were performed to evaluate associations between 
regional brain volumes and binary variables indicating 1) a CD4+ ≤ 200/μL (1) or CD4+ > 200/μL (0) and 2) a detectable 
(1) or undetectable (0) VL.
An AIDS-defining immunosuppression status (CD4+ ≤ 200/μL) was associated with smaller putamen volumes in 
participants not taking cART (d = 0.41, p = 0.0007; eTable 7). A dVL > 400 copies/mL was associated with larger ventricles 
in the full group (d = 0.20, p = 0.0022), participants taking cART (d = 0.33, p = 0.0011), and males (d = 0.31; p = 0.0002) 
(eTable 8). In both participants taking cART and males, a dVL was associated with smaller hippocampal volumes (taking 
cART: d = -0.28, p = 0.0055; Male: d = -0.26; p = 0.0023). Male participants with a dVL additionally had significantly 
smaller thalamic volumes (d = -0.23, p = 0.0062). 
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eTable 1. Study Inclusion and Exclusion Criteria, by Site. Inclusion and exclusion criteria for study participants. 
Site name Inclusion Criteria Exclusion Criteria Reference 
HIVNC Consortium (7 Sites), 
United States 
HIV positive; Age > 18 
years; On stable cART ≥ 
12 weeks; Nadir CD4 < 
200 cells/μL
Major psychiatric illness; Confounding neurological 
disorders; Brain infection other than HIV; Hepatic 
dysfunction; Diabetes mellitus; Active substance abuse or 
related medical complications within 6 months of study 
Nir et al. 20193 
University of Hawaii, 
United States (Chang/ Ernst) 
HIV positive; Age > 18; 
On stable cART > 6 
months or no cART; 
Nadir CD4 ≤ 500 
cells/μL.  
Any illness known to alter brain structures; History of illicit 
drug or alcohol dependence by DSM-IV criteria; Positive 
urine toxicology screen; Head trauma with loss of 
consciousness > 30min; Severe abnormalities on screening 
laboratory tests that might confound brain imaging measures 
or function; Any contraindications for MRI. 
Chang et al. 
20114 
University of Hawaii, 
United States (Shikuma) 
HIV positive; Age > 40 
years; On stable cART ≥ 3 
months  
Uncontrolled major affective disorder; Active psychosis; 
Loss of consciousness > 5 min; Pregnant or breastfeeding; 
Any past or present confounding condition (e.g. CNS 
infection, TBI, stroke, substance abuse) 
Kallianpur et 
al. 20165 
University of California, 
San Francisco,  
United States 
HIV positive; Age > 60 
years 
Learning disabilities; Major psychiatric or neurological 
illness; Current or past brain infection; Major systemic 
illness or head injury 




HIV positive; Age > 18 
years 
Note: Some HIV+ 
participants presented 
with Hepatitis C 
History of head injury with loss of consciousness > 10 min; 
Neurological conditions including dementia unrelated to 
HIV, seizure disorder, stroke, and opportunistic infection of 
the brain; Severe psychiatric illness that may impact brain 
function (e.g., schizophrenia); Diagnosis of alcohol or 




University of California, 
Los Angeles,  
United States (Hinkin) 
HIV positive; Age > 18 
years 
Neurological, psychiatric, and medical confounds (e.g., 
history of seizure disorder or other neurologic disorder; 
history of concussion or TBI; history of Axis I psychiatric 
disorder or current substance use disorder; current 
prescription for psychotropic medication, except for 
anxiolytics and antidepressants; current substance 
dependence or methamphetamine use); Comorbid CNS 
infection (e.g. Hepatitis C); HIV-associated CNS 
opportunistic infection (e.g. toxoplasmosis) or neoplasm; 
MRI contraindications 
Kuhn et al. 
20178 
University of California, 
Los Angeles,  
United States (Thames) 
HIV positive; Age > 18 
years; Chronic HIV 
infection (mean duration 
of 12 years); On stable 
cART ≥ 3 months; 
Clinically stable (as 
indicated by CD4+ 
cells/μL); Score ≥ 26 on 
Mini-Mental Status Exam 
Current abuse of cocaine/amphetamines; Past stimulant 
abuse/dependence; Current/past diagnosis of psychotic 
spectrum disorder; CNS confounds (e.g., HIV-associated 
opportunistic infections or neuro-syphilis); Hepatitis C 
coinfection; Major head injury; MRI contraindication 
Thames et al. 
20189 
University of New South Wales, 
Australia (Brew) 
HIV positive; Age > 18 
years; On stable cART ≥ 
12 months 
Contraindication to MRI; Comorbid CNS infection, tumor or 
stroke 
Changanti et al 
201710 
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University of New South Wales, 
Australia (Cysique) 
HIV positive; Age > 45 
years; On stable cART ≥ 6 
months; Nadir CD4 ≤ 350 
cells/μL; Known HIV 
duration ≥ 5 years; No 
active opportunistic 
disease 
Note: HIV+ participants 
all male 
MRI contraindication; History of neurological disorders 
predating HIV diagnosis (e.g., epilepsy, traumatic brain 
injury, Parkinson’s Disease, Multiple Sclerosis, Alzheimer’s 
disease, or Vascular Dementia); Psychiatric disorders on the 
psychotic axis (e.g., schizophrenia); Current substance use 
disorders (within 12 months of study enrolment; recreational 
use of marijuana was not set as a criterion for exclusion 
because it would exclude a large number of HIV+ 
individuals); Participants not excluded on the basis of current 
depressive symptoms; Hepatitis C status was recorded from 
the participants' medical records and participants were 
included only if successfully treated and/or inactive (N=2) 
Nichols et al. 
201911 
SEARCH 011 Consortium, 
Thailand 
HIV positive; Age > 18 
years; cART-naïve; CD4 
< 350 cells/μL or 
symptomatic HIV
Head injury; Current substance abuse; Acute concurrent 
illness; Neurologic or psychiatric conditions; Learning 
disabilities; Positive hepatitis C screen; Contraindications for 
MRI; Significant laboratory abnormalities (e.g. creatinine, 
ALT, hemoglobin) 
Heaps et al. 
201512 
University of Cape Town, 
South Africa 
HIV positive; Age 18 to 
50 years to avoid CNS 
complications associated 
with neurodevelopment 
and advanced age; at least 
5 years of formal 
education; cART 
initiation within 3 months 
of enrollment; Xhosa as 
the primary language 
Note: Predominantly 
female; 100% detectable 
viral load 
Major psychiatric conditions (schizophrenia, bipolar 
disorder, post- traumatic stress disorder, etc.); Neurological 
disease that could affect brain integrity (e.g., multiple 
sclerosis); CDC stage A; Opportunistic infections of the CNS 
(e.g., cytomegalovirus encephalitis, cryptococcal meningitis, 
toxo- plasma encephalitis); Lifetime history of head injury 
resulting in loss of consciousness >30 min; Current substance 
use disorder as determined by the Mini- International 
Neuropsychiatric Interview Plus 




HIV positive; age > 18 
years 
CNS opportunistic infections; Change in psychotropic 
therapy < 3 weeks; Any neurological history 
Vassallo et al. 
201514 
University of Novi Sad, 
Serbia 
HIV positive; Age > 18 
yrs; On stable cART ≥ 12 
months; Nadir CD4+ ≤ 
250 cells/μL  
A history of neurological disorders predating HIV (e.g., 
epilepsy, brain tumor, TBI, Parkinson’s Disease, Multiple 
Sclerosis, Alzheimer’s disease, or Vascular Dementia); 
Psychiatric disorders on the psychotic axis (e.g., 
schizophrenia); Cardiovascular diseases (hypertension, 
chronic occlusive carotid disease, ischemic vascular 
dementia); History of or current substance use disorders; 
Hepatitis C (HCV) or Hepatitis B positive  
Boban et al. 
201715 
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eTable 2. Study T1-Weighted MRI Acquisition Parameters, by Site. 
Site Scanner Acquisition Parameters 
HIVNC Consortium, 
United States 
1.5T GE Signa, 
Siemens 
Symphony/Sonata 
GE SPGR; TR=2-23 ms; TE=3-9 ms; flip angle=30°; 
matrix size = 256 × 128; voxel size=1x1x1.2-1.5 mm 
Siemens: TR=20-24 ms; TE=10.1 ms; flip angle = 30°; 
matrix size = 256 × 192; voxel size=1x1x1.2-1.3 mm 
University of Hawaii, 
United States (Chang/ Ernst) 
3T Siemens 
TrioTim 
MP-RAGE; TR=2200 ms; TE=4.48 ms; TI=1000 ms; FOV = 256mm; 
160 slices; voxel size=1x1x1mm 
University of Hawaii, 
United States (Shikuma) 
3T Phillips 
Achieva 
3D TFE; TR=6.9 ms; TE = 3.2 ms; flip angle = 8°; FOV = 256mm; 
voxel size=1x1x1.2 mm
University of California, 
San Francisco, United States 
3T Siemens 
TrioTim 
MP-RAGE; TR=2300 ms; TE=2.98 ms; flip angle=9°; FOV = 256mm; 





MP-RAGE; TR=2250 ms; TE=3.06 ms; flip angle=9°; FOV = 220 mm; 
matrix = 256×256, slice thickness = 0.86 mm 
University of California, Los 
Angeles, United States (Hinken) 
3T Siemens 
TrioTim 
MP-RAGE; TR=2200 ms; TE=2.2 ms; matrix size = 256 × 256; 
FOV 240 mm; 176 slices; slice thickness = 1 mm 
University of California, Los 
Angeles, United States (Thames) 
3T Siemens 
TrioTim 
MP-RAGE; TR = 450.0 ms; TE = 10.0 ms; flip angle: 8°; 
FOV 256 mm; matrix =256x219; voxel size =1.0x0.94x0.94 mm 




3D TFE; TR=5.3 ms; TE=2.4ms; flip angle = 18°, 256x256 matrix; 
180 slices; voxel size=1x1x1 mm 




3D TFE; TR= 6.39ms; TE=2.9 ms; flip angle: 8°; FOV 256 mm; 
190 slices, voxel size=1x1x1 mm 




MP-RAGE; TR=2400 ms; TE=2.38 ms; flip angle=8°; 162 slices; 
voxel size=1x1x1 mm 




MP-RAGE; TR=2400 ms; TE=2.38 ms; TI=1000 ms; flip angle=8°; 





SPGR; TR =12.4 ms, TE = 5.2 ms, flip angle = 18°; FOV = 240 mm; 
256x256 matrix; voxel size=0.6x0.6x0.6 mm 




MP-RAGE; TR = 2300 ms; TE=2.97 ms; FOV 256 mm; 
voxel size=1x1x1 mm 
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eTable 3. Data Quality Assurance and Exclusion. We note the initial number of participants with MRI from each 
study and the number of participants excluded from the final analysis. The row sum of excluded individuals may exceed 







Missing Data Failed Quality Assurance 




Age Sex CD4+ cART 
HIVNC Consortium, 
United States 
236 218 2 2 7 -- 6 3 
University of Hawaii, 
United States (Chang/Ernst) 
192 175 -- 1* 6 1 8 1 
University of Hawaii, 
United States (Shikuma) 
53 53 -- -- -- -- -- 
University of California, 
San Francisco, United States 
55 50 2 -- 3 -- -- -- 
Brown University, 
United States 
101 79 1 1 -- -- 21 -- 
University of California,  
Los Angeles, United States (Hinken) 
13 12 -- -- 1 -- -- -- 
University of California, 
Los Angeles, United States (Thames) 
70 51 -- 3* 6 -- 10 -- 
University of New South Wales, 
Australia (Brew) 
42 39 -- -- 1 -- -- -- 
University of New South Wales, 
Australia (Cysique) 
82 68 -- -- -- -- 14 -- 
SEARCH 011 Consortium, 
Thailand 
62 61 -- -- 1 -- -- -- 
University of Cape Town, 
South Africa 
183 181 -- -- -- -- 2 -- 
Nice University, 
France 
161 155 -- -- -- -- 6 -- 
University of Novi Sad, 
Serbia 
87 61 6 -- 4 12 9 -- 
* Transgender individuals
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eTable 4. Detectable Viral Load Thresholds, by Site. Approximate detectable plasma RNA viral load threshold for each site. 
The highest site-specific assay detection threshold, 400 copies/mL, was used to define a common, harmonized detectable VL 
threshold across all collection sites. 
Site 
Detectable Viral Load Threshold 
(copies/mL) 
HIVNC Consortium (7 Sites), United States 50-400 
Site 1: 
University of California, 
San Diego 
50 
Site 2:  
Harbor UCLA Medical Center 
75 












Site 7:  
University of California, 
Los Angeles 
400 
University of Hawaii,  
United States (Chang/ Ernst) 
75 
University of Hawaii,  
United States (Shikuma) 
50 
University of California, 





University of California, Los Angeles, 
United States (Hinken) 
48 
University of California, Los Angeles, 
United States (Thames) 
19 
University of New South Wales, Australia 
(Brew) 
20 
University of New South Wales, Australia 
(Cysique) 
50 
SEARCH 011 Study, 
Thailand 
40 






University of Novi Sad, 
Serbia 
50 
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eTable 5. Age Feasibility Study Mega-Analysis Results. Partial correlation coefficients (r), unstandardized regression slopes (b-values reflecting change in 
volume (mm3) for every year of age), standard errors (SE), and p-values from associations between age and regional brain volumes across all HIV+ participants, 
and by cART status and sex. 
ROI 
Total (n=1,203) Taking cART (n=897) Not Taking cART (n=306) Male (n=880) Female (n=323) 
r b SE p r b SE p r b SE p r b SE p r b SE p 
Thalamus -0.25 -26.20 2.92 1.11E-18** -0.31 -33.69 3.55 2.03E-20** -0.12 -13.62 6.43 0.035* -0.35 -29.66 2.68 1.02E-26** -0.24 -22.32 5.22 2.53E-5** 
Caudate -0.13 -7.13 1.59 8.47E-6** -0.10 -6.04 2.02 0.0029** -0.21 -12.29 3.39 3.40E-4** -0.16 -7.26 1.48 1.21E-6** -0.16 -8.29 2.91 0.0046** 
Putamen -0.30 -24.30 2.26 8.21E-26** -0.28 -25.58 2.94 1.49E-17** -0.27 -21.37 4.41 2.06E-6** -0.36 -24.86 2.20 8.23E-28** -0.37 -26.38 3.76 1.41E-11** 
Globus Pallidus -0.21 -6.07 0.81 1.65E-13** -0.20 -6.30 1.07 5.37E-9** -0.22 -6.23 1.61 1.29E-4** -0.24 -5.61 0.79 2.25E-12** -0.30 -7.59 1.37 6.21E-8** 
Hippocampus -0.17 -9.12 1.55 5.02E-9** -0.16 -9.41 1.96 1.77E-6** -0.13 -7.27 3.32 0.029* -0.24 -10.57 1.47 1.20E-12** -0.16 -7.67 2.71 0.005** 
Amygdala -0.15 -3.77 0.72 1.62E-7** -0.14 -3.75 0.91 4.40E-5** -0.11 -2.76 1.43 0.054* -0.21 -4.21 0.68 9.56E-10** -0.18 -3.95 1.26 0.0019** 
Accumbens -0.26 -3.33 0.35 2.49E-20** -0.24 -3.29 0.45 9.39E-13** -0.24 -3.17 0.74 2.51E-5** -0.29 -3.03 0.35 9.34E-18** -0.34 -3.92 0.61 5.70E-10** 
Lateral 
Ventricles 
0.25 350.29 39.43 2.35E-18** 0.23 378.63 53.16 2.22E-12** 0.16 211.92 74.93 0.005** 0.33 397.61 39.39 1.02E-22** 0.23 238.27 56.98 3.78E-5** 
**Significant at Bonferroni corrected threshold for tests in 8 regions of interest, p ≤ 0.0063 
*Suggestive at p ≤ 0.05
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eTable 6. HIV Subcortical Volume Comparisons with Healthy Lifespan Centiles. Results from the Kullback–Leibler divergence, corresponding permutations, 
and chi-squared goodness of fit tests used to determine whether the observed volumes in the full HIV+ group, and subgroups stratified by cART status, CD4+ cell 
count, and viral load (VL), were likely to come from the distributions derived from healthy controls. 
ROI 




































L Thalamus 0.41 0.0001 0.0001 0.38 0.0001 0.0001 0.42 0.0001 0.0001 0.41 0.0001 0.0001 0.37 0.0001 0.0001 0.41 0.0001 0.0001 0.39 0.0001 0.0001 
R Thalamus 0.41 0.0001 0.0001 0.41 0.0001 0.0001 0.44 0.0001 0.0001 0.42 0.0001 0.0001 0.44 0.0001 0.0001 0.39 0.0001 0.0001 0.41 0.0001 0.0001 
L Hippocampus 0.34 0.0001 0.0001 0.39 0.0001 0.0001 0.34 0.0001 0.0001 0.35 0.0001 0.0001 0.37 0.0001 0.0001 0.40 0.0001 0.0001 0.35 0.0001 0.0001 
R Hippocampus 0.37 0.0001 0.0001 0.39 0.0001 0.0001 0.40 0.0001 0.0001 0.37 0.0001 0.0001 0.35 0.0001 0.0001 0.35 0.0001 0.0001 0.37 0.0001 0.0001 
L Ventricle 0.29 0.0001 0.0001 0.34 0.0001 0.0001 0.29 0.0001 0.0001 0.31 0.0001 0.0001 0.33 0.0001 0.0001 0.30 0.0001 0.0001 0.32 0.0001 0.0001 
R Ventricle 0.34 0.0001 0.0001 0.32 0.0001 0.0001 0.30 0.0009 0.0001 0.32 0.0001 0.0001 0.29 0.0001 0.0001 0.30 0.0001 0.0001 0.27 0.0002 0.0001 
L Amygdala 0.37 0.0001 0.0001 0.43 0.0001 0.0001 0.42 0.0001 0.0001 0.39 0.0001 0.0001 0.37 0.0001 0.0001 0.43 0.0001 0.0001 0.38 0.0001 0.0001 
R Amygdala 0.43 0.0001 0.0001 0.44 0.0001 0.0001 0.39 0.0001 0.0001 0.44 0.0001 0.0001 0.42 0.0001 0.0001 0.42 0.0001 0.0001 0.44 0.0001 0.0001 
L Caudate 0.30 0.0001 0.0001 0.29 0.0001 0.0001 0.28 0.0001 0.0001 0.31 0.0001 0.0001 0.32 0.0001 0.0001 0.33 0.0001 0.0001 0.28 0.0001 0.0002 
R Caudate 0.36 0.0001 0.0001 0.33 0.0001 0.0001 0.33 0.0001 0.0001 0.32 0.0001 0.0658 0.33 0.0001 0.0001 0.34 0.0001 0.0001 0.28 0.0004 0.0001 
L Globus Pallidus 0.39 0.0001 0.0001 0.40 0.0001 0.0001 0.37 0.0001 0.0001 0.41 0.0001 0.0001 0.39 0.0001 0.0001 0.41 0.0001 0.0001 0.40 0.0001 0.0001 
R Globus Pallidus 0.39 0.0001 0.0001 0.37 0.0001 0.0001 0.40 0.0001 0.0001 0.37 0.0001 0.0001 0.42 0.0001 0.0001 0.36 0.0001 0.0001 0.39 0.0001 0.0001 
L Putamen 0.40 0.0001 0.0001 0.37 0.0001 0.0001 0.38 0.0001 0.0001 0.43 0.0001 0.0001 0.38 0.0001 0.0001 0.36 0.0001 0.0001 0.34 0.0001 0.0001 
R Putamen 0.38 0.0001 0.0001 0.38 0.0001 0.0001 0.38 0.0001 0.0001 0.42 0.0001 0.0001 0.42 0.0001 0.0001 0.36 0.0001 0.0001 0.38 0.0001 0.0001 
L Accumbens 0.36 0.0001 0.0001 0.36 0.0001 0.0001 0.36 0.0001 0.0002 0.35 0.0001 0.0081 0.35 0.0001 0.0001 0.36 0.0001 0.0002 0.36 0.0001 0.0001 
R Accumbens 0.43 0.0001 0.0001 0.40 0.0001 0.0001 0.42 0.0001 0.0001 0.37 0.0001 0.0001 0.42 0.0001 0.0001 0.40 0.0001 0.0001 0.38 0.0001 0.0001 
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eTable 7. Lateralized Associations with CD4+ Cell Counts and Detectable Viral Load. Associations between left and right 
subcortical volumes and CD4+ cell count or detectable viral load (dVL) at the time of scan for regions that showed significant 
associations when averaged bilaterally in primary analyses across HIV+ participants. 
ROI 
CD4+ (n=1,203) dVL (n=1,161) 
Left Right Left Right 
r b SE p r b SE p d SE p d SE p 
Thalamus 0.093 31.18 9.73 0.0014** 0.10 32.84 9.14 0.0003** -- -- -- -- -- -- 
Hippocampus 0.11 18.23 5.02 0.0003** 0.090 15.23 4.90 0.0019** -0.16 0.060 0.0066* -0.16 0.060 0.0074* 
Lateral 
Ventricles 
-0.091 -204.52 65.49 0.0018** -0.090 -188.92 60.43 0.0019** -- -- -- -- -- -- 
**Significant at Bonferroni corrected threshold for tests in 8 regions of interest p ≤ 0.0063 
*Suggestive at p ≤ 0.05
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eTable 8. Dichotomized CD4+ Cell Count Threshold Analysis Results. Effect sizes (d) for associations between regional brain volumes and an AIDS-defining 
immunosuppression status (CD4+ cell count ≤ 200/μL) across HIV+ individuals, and by cART status and sex. 
ROI 
Total (n=1,203) Taking cART (n=897) Not Taking cART (n=306) Male (n=880) Female (n=323) 
d SE p d SE p d SE p d SE p d SE p 
Thalamus -0.065 0.073 0.38 0.014 0.10 0.89 -0.18 0.12 0.135 0.028 0.095 0.77 -0.19 0.12 0.12 
Caudate -0.057 0.073 0.44 -0.047 0.10 0.66 -0.081 0.12 0.49 -0.067 0.095 0.49 -0.012 0.12 0.93 
Putamen -0.18 0.073 0.017* -0.057 0.10 0.59 -0.41 0.12 0.0007** -0.19 0.095 0.046* -0.16 0.12 0.21 
Globus Pallidus -0.12 0.073 0.094 -0.052 0.10 0.62 -0.28 0.12 0.021* -0.10 0.095 0.29 -0.13 0.12 0.30 
Hippocampus -0.16 0.073 0.034* -0.087 0.10 0.41 -0.26 0.12 0.029* -0.19 0.095 0.045* -0.095 0.12 0.44 
Amygdala -0.13 0.073 0.076 -0.092 0.10 0.38 -0.22 0.12 0.070 -0.12 0.095 0.20 -0.15 0.12 0.22 
Accumbens -0.15 0.073 0.049* -0.060 0.10 0.57 -0.29 0.12 0.016* -0.063 0.095 0.51 -0.31 0.12 0.013* 
Lateral Ventricles 0.098 0.073 0.19 0.084 0.10 0.42 0.14 0.12 0.24 0.095 0.095 0.32 0.16 0.12 0.20 
% with CD4+ Count 
< 200/μL 
19.1% 11.9% 40.2% 14.9 % 30.7% 
**Significant at Bonferroni corrected threshold for tests in 8 regions of interest, p ≤ 0.0063 
*Suggestive at p ≤ 0.05
eTable 9. Harmonized Viral Load Threshold Analysis Results. Effect sizes (d) for associations between regional brain volumes and dVL > 400 copies/mL 
across HIV+ individuals, and by cART status and sex. We note that dVL associations in those off treatment included only a limited number of individuals with 
undetectable VL (n=24), and should be interpreted with caution.  
ROI 
Total (n=1,156) Taking cART (n=884) Not Taking cART (n=272) Male (n=863) Female (n=293) 
d SE p d SE p d SE p d SE p d SE p 
Thalamus -0.15 0.063 0.016* -0.26 0.10 0.012* -0.11 0.21 0.60 -0.23 0.083 0.0062** 0.063 0.12 0.61 
Caudate -0.017 0.063 0.79 0.020 0.10 0.84 -0.22 0.21 0.30 0.007 0.082 0.94 -0.088 0.12 0.48 
Putamen -0.021 0.063 0.74 -0.037 0.10 0.71 0.006 0.21 0.98 -0.049 0.082 0.56 0.025 0.12 0.84 
Globus Pallidus -0.041 0.063 0.52 0.006 0.10 0.95 -0.38 0.21 0.08 -0.019 0.082 0.82 -0.14 0.12 0.25 
Hippocampus -0.16 0.063 0.011* -0.28 0.10 0.0055** -0.004 0.21 0.99 -0.26 0.083 0.0023** 0.031 0.12 0.80 
Amygdala -0.079 0.063 0.22 -0.14 0.10 0.17 -0.003 0.21 0.99 -0.12 0.083 0.16 -0.006 0.12 0.96 
Accumbens -0.11 0.063 0.098 -0.19 0.10 0.060 0.037 0.21 0.87 -0.22 0.083 0.009* 0.18 0.12 0.15 
Lateral Ventricles 0.20 0.064 0.0022** 0.33 0.10 0.0011** 0.024 0.21 0.91 0.31 0.083 0.0002** -0.078 0.12 0.53 
% with Viral Load 
> 400 copies/mL
31.4% 13.0% 91.2% 21.8% 59.7% 
**Significant at Bonferroni corrected threshold for tests in 8 regions of interest, p ≤ 0.0063 
*Suggestive at p ≤ 0.05
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eFigure 1. Age Association Forest Plots: Putamen, Globus Pallidus, Hippocampus, and Thalamus. Forest plot of effect 
sizes (r-values and 95% confidence intervals) for associations between age and putamen, globus pallidus, hippocampal or 
thalamic volumes across all 19 sites. 
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eFigure 2. Age Association Forest Plots: Accumbens, Amygdala, Caudate, and Ventricles. Forest plot of effect sizes (r-
values and 95% confidence intervals) for associations between age and accumbens, amygdala, caudate or ventricular volumes 
across 19 sites.  
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eFigure 3. Histogram of HIV-positive Subcortical Volumes with Respect to Healthy Lifespan Centile Values. Percent of 
HIV+ participants, across the full cohort, with subcortical volumes that fall into each healthy subcortical volume centile bin as 
defined in Table S6 of Dima et al. (2020). The dotted line marks the 50th percentile. 
eFigure 4. Histogram of HIV-positive Subcortical Volumes with Respect to Healthy Lifespan Centile Values, by cART 
Status. Percent of HIV+ participants taking or not taking cART (cART+/cART-) with subcortical volumes that fall into each 
healthy subcortical volume centile bin as defined in Table S6 of Dima et al. (2020). The dotted line marks the 50th percentile. 
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eFigure 5. Histogram of HIV-positive Subcortical Volumes with Respect to Healthy Lifespan Centile Values, by CD4+ 
Cell Count (> 200/μL). Percent of HIV+ participants with either CD4+ cell count ≤ 200/μL or > 200/μL with subcortical 
volumes that fall into each healthy subcortical volume centile bin as defined in Table S6 of Dima et al. (2020). The dotted line 
marks the 50th percentile. 
eFigure 6. Histogram of HIV-positive Subcortical Volumes with Respect to Healthy Lifespan Centile Values, by Viral 
Load Detectability. Percent of HIV+ participants with either detectable or undetectable viral loads (dVL or uVL, respectively) 
with subcortical volumes that fall into each healthy subcortical volume centile bin as defined in Table S6 of Dima et al. (2020). 
The dotted line marks the 50th percentile. 
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eFigure 7. CD4+ Cell Count Association Forest Plots: Putamen, Globus Pallidus, Hippocampus, and Thalamus. Forest 
plot of effect sizes (r-values and 95% confidence intervals) for associations between CD4+ cell count and putamen, globus 
pallidus, hippocampal or thalamic volumes across 19 sites. 
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eFigure 8. CD4+ Cell Count Association Forest Plots: Accumbens, Amygdala, Caudate, and Ventricles. Forest plot of 
effect sizes (r-values and 95% confidence intervals) for associations between CD4+ cell count and accumbens, amygdala, 
caudate or ventricular volumes across 19 sites. 
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eFigure 9. CD4+ Cell Count and Detectable Viral Load Effect Sizes in Males Compared to Females. Effect sizes in males 
compared to females for each ROI were highly correlated (CD4+: Pearson’s correlation r = 0.91, p =0.002; dVL: r = 0.22, p = 
0.60). 
© 2021 T. M. Nir et al. JAMA Network Open. 
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